Schering-Plough Corporation 1999 10-K Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 1999. Schering-Plough Corporation is a global pharmaceutical holding company engaged in the discovery, development, manufacturing, and marketing of prescription drugs, animal health products, and over-the-counter (OTC) consumer health products. Effective January 1, 1999, the company reorganized into a single reporting segment, consolidating its previous pharmaceuticals and health care units. The company employs approximately 26,500 people worldwide.
Key Financial Metrics
Consolidated net sales for 1999 were $9,176 million, an increase from $8,077 million in 1998. Research and development (R&D) expenditures totaled $1,191 million, representing approximately 13% of consolidated net sales. The filing text does not provide specific values for net income, operating margins, cash flow, total debt, or liquidity ratios, as the detailed financial statements are incorporated by reference from the Annual Report to Shareholders.
Material Changes and Sales by Category
Net sales growth was driven primarily by the Allergy & Respiratory and Anti-infective/Anticancer categories. Key sales figures (in millions) for 1999 versus 1998 include:
- Allergy & Respiratory: $3,850 (1999) vs. $3,375 (1998)
- Anti-infective and Anticancer: $1,738 (1999) vs. $1,263 (1998)
- Animal Health: $678 (1999) vs. $647 (1998)
- Cardiovasculars: $673 (1999) vs. $750 (1998) (Decline)
- OTC and Sun Care: Relatively stable, with OTC at $221 and Sun Care at $194.
The company noted that 12% of consolidated net sales in 1999 were made to a single distributor, McKesson HBOC Inc.
Outlook, Risks, and Legal Proceedings
Patent Expirations: The company faces significant patent cliffs. The U.S. compound patent for CLARITIN (loratadine) expires in 2002, and the desloratadine patent expires in 2004. These patents are currently subject to litigation.
Legal Proceedings:
- DES Litigation: The company is a defendant in 235 lawsuits involving synthetic estrogens with claims exceeding $1.5 billion. Management believes material liability in excess of accrued amounts is remote.
- Antitrust Actions: The company is involved in over 110 antitrust actions regarding pricing and trade restraints. A federal class action was settled for $22 million. The FTC is investigating potential price-fixing conspiracies.
- Government Investigations: The U.S. Attorney's Office issued a subpoena regarding disease management programs and rebate calculations under HIPAA.
- Patent Disputes: Multiple generic manufacturers (Geneva, Copley, Teva, Novex, Zenith, Andrx) have challenged CLARITIN patents. Hoffmann-La Roche has sued regarding PEG-INTRON patents.
Risks: Forward-looking statements highlight risks including generic competition, pricing pressure from managed care, regulatory delays, and the uncertainty of product development.
Investor Verification Checklist
- Verify the specific net income and operating margin figures in the incorporated Annual Report to Shareholders, as they are not explicitly stated in this text.
- Monitor the status of CLARITIN patent litigation and the potential impact of the 2002/2004 patent expirations on future revenue.
- Review the outcomes of the ongoing FTC price-fixing investigation and the U.S. Attorney's Office inquiry into disease management rebates.
- Assess the progress of the R&D pipeline, particularly in oncology and infectious diseases, given the heavy reliance on existing blockbuster drugs.
- Confirm the company's cash flow position and debt levels in the full financial statements to evaluate liquidity.